NICE Gives Landmark Nod To Bayer's Vitrakvi
First Histology-Independent Therapy For Patients In England
Vitrakvi is the first in a new generation of tumor-agnostic drugs to be made available on the NHS after Bayer and NICE finally reached agreement over pricing and access while more data is collected on its clinical effectiveness.
